3rd Annual Virtual Biosymposium
We invite you to our 3rd Annual Virtual Biosymposium. This year, we will explore novel analytical characterization and quantitation of emerging and established modalities, such as mRNA, oligos and ADCs, with experts from Roche and Phenomenex.
Key Learning Points
- Apply novel approaches for characterizing both established and emerging biotherapeutic modalities.
- Discuss key considerations when developing methods to characterize and quantify biomolecules.
- Learn the importance of fit-for-purpose analytical methods in supporting critical drug development decisions.
Who Should Attend
- Scientists developing liquid chromatography (LC) methods, including SEC, utilizing LC friendly detectors for the characterization of established and modern biotherapeutic modalities.
Agenda
Suitability of the Phenomenex dSEC-7 Column for Aggregate Analysis – An Industrial Perspective
- Carsten Elger, Analytical Development Scientist at Roche Diagnostics GmbH
A Separation Study of Oligonucleotides & mRNA by IP-RP on Various Stationary Phases Complemented by SEC
- Dr. Shilin Cheung, Ph.D., New Product Development at Phenomenex
DAR Analysis for ADC Characterization under Native LC-MS Conditions
- Mihir Thakar, Product Manager at Phenomenex
Speaker: Carsten Elger (Analytical Development Scientist at Roche Diagnostics GmbH)
Carsten Elger continues his 20 plus years tenure at Roche, focusing on HPLC analysis for therapeutic proteins. For the last five years, his work has been around analytical development and quality control for gene therapies.
Speaker: Dr. Shilin Cheung, Ph.D. (New Product Development at Phenomenex)
Dr. Cheung received her BS (2006) and Ph.D. (2012) in Bioanalytical Chemistry from the University of Toronto. She has developed, qualified, and validated innovative analytical methods in CE based microfluidics, automated low volume UV-vis spec., and UHPLC assays. Her methods have been applied to manufacturing process developments, formulation and stability and DS/DP characterization and specification testing. At the Phenomenex Innovation Campus she is focused on developing fit for purpose analytical methods to help advance developments in gene therapeutics.
Speaker: Mihir Thakar (Product Manager at Phenomenex)
Mihir holds a master’s degree in Biotechnology. He has over a decade of experience working with various biopharma companies in the characterization of therapeutic peptides, proteins, and oligonucleotides. He has been associated with Phenomenex for more than 7 years, serving in various functions including as a Business Development Manager for Biologics. At present, he has been working as a Global Product Manager for the biopharma segment.
